NasdaqGM · Biotechnology

Kalaris Therapeutics (KLRS)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+350.9%

$18.71 average target

$4.15+0.03 (+0.7%)Latest market snapshot · Yahoo Finance

Market cap$98.8M

Cash$93.5M

Quarterly burn$11.6M

Pipeline assets1

Short float5.0%

Market expectations

Analyst Ratings & Price Targets

Data may be delayed

Street view at a glance

The average target implies 350.9% upsideTargets are estimates—not guarantees—and can change after company updates.

$18.71Average target

Wall Street consensus

Strong BuyBased on 7 analyst opinions

8ratings

Buy 7Hold 1Sell 0

Price-target range

$18.71

+350.9%

Low $7.00High $25.00

CurrentAverage

Bear case$7.00+68.7%

Base case$18.71+350.9%

Bull case$25.00+502.4%

Analyst coverage7published opinions

Bullish share88%buy recommendations

Target spread$18low-to-high dispersion

Consensus score1.51.0 is strongest

Recommendation mix

Current rating breakdown

8 tracked ratings

Company profile

About Kalaris Therapeutics

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.